Corporate Profile
Cognition Therapeutics is a clinical-stage biopharmaceutical company leveraging our expertise in the σ-2 (sigma-2) receptor to develop innovative, small molecule therapeutics targeting age-related degenerative diseases. Our initial focus is on degenerative diseases of the CNS and retina such as Alzheimer’s disease, dementia with Lewy bodies and dry age-related macular degeneration.
Data Provided by Refinitiv. Minimum 15 minutes delayed.
News Releases
Sep 07, 2023
Aug 30, 2023
Aug 08, 2023
Events
Sep 26, 2023 at 9:20 AM EDT
Sep 18 - Sep 19, 2023
Sep 13, 2023 at 4:00 PM EDT
Latest SEC Filings
Form | Filing date | Description |
---|---|---|
D | Notice of Exempt Offering of Securities |
|
D | Notice of Exempt Offering of Securities |
|
D | Notice of Exempt Offering of Securities |